<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937261</url>
  </required_header>
  <id_info>
    <org_study_id>BIRN 2008-6382</org_study_id>
    <nct_id>NCT00937261</nct_id>
  </id_info>
  <brief_title>Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning</brief_title>
  <official_title>Contrasting the Brain Effects of Risperidone and Invega With fMRI and PET Scanning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand brain function and psychiatric and
      neurological illness when taking Invega or Risperdal. The objective is to compare the brain
      effects of Invega to Risperdal in patients with Schizophrenia. This comparison will be
      evaluated with PET imaging, fMRI, and neurological ratings and assessments.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of BOLD signal activation and FDG metabolism of the DLPFC, superior temporal gyrus and amygdala, and their interaction between Invega and Risperdal</measure>
    <time_frame>approximately 6-10 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Risperdal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperdal 2-8mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Invega</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Invega 6-12mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>2mg - 8mg per day, for the duration of participation in the study</description>
    <arm_group_label>Risperdal</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paliperidone</intervention_name>
    <description>6mg - 12mg per day, for the duration of participation in the study</description>
    <arm_group_label>Invega</arm_group_label>
    <other_name>Invega</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  are currently taking Risperdal and have been on the medication for at least three
             weeks

          -  are diagnosed with schizophrenia

          -  are able to provide written informed consent

          -  can safely have an MRI

        Exclusion Criteria:

          -  are treatment resistant or intolerant to Risperdal

          -  have participated in another drug study in the past 28 days

          -  are pregnant or trying to become pregnant or are breastfeeding

          -  are colorblind

          -  have a history of alcohol, cannabis, or cocaine abuse within two weeks prior to the
             study

          -  have a current or past history of a major medical illness or have abnormal lab values
             which the study doctor feels is significant

          -  certain medications are also exclusionary including aripiprazole.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven G Potkin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liv McMillan, B.S.</last_name>
    <phone>949-824-3770</phone>
    <email>liv@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven G Potkin, M.D.</last_name>
    <phone>714-456-5697</phone>
    <email>sgpotkin@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven G Potkin, M.D.</last_name>
      <phone>949-824-8040</phone>
      <email>sgpotkin@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Liv McMillan, B.S.</last_name>
      <phone>949-824-3770</phone>
      <email>liv@uci.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Steven G Potkin, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>October 27, 2010</last_update_submitted>
  <last_update_submitted_qc>October 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Steven G. Potkin, M.D.</name_title>
    <organization>UC Irvine -FBIRN</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Paliperidone Palmitate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 19, 2013</submitted>
    <returned>September 3, 2013</returned>
    <submitted>January 25, 2017</submitted>
    <returned>March 14, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

